4//SEC Filing
SANG CHARLES 4
Accession 0001209191-20-030299
CIK 0001478320other
Filed
May 17, 8:00 PM ET
Accepted
May 18, 9:00 PM ET
Size
13.0 KB
Accession
0001209191-20-030299
Insider Transaction Report
Form 4
SANG CHARLES
Sr VP, Clinical Diagnostics
Transactions
- Exercise/Conversion
Common Stock
2020-05-15$6.32/sh+20,000$126,400→ 20,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-05-15−20,000→ 80,000 totalExercise: $6.32Exp: 2026-04-29→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2020-05-15$6.55/sh+20,000$131,000→ 40,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-05-15−20,000→ 230,000 totalExercise: $6.55Exp: 2028-02-07→ Common Stock (20,000 underlying) - Sale
Common Stock
2020-05-15$38.01/sh−40,000$1,520,400→ 0 total
Footnotes (3)
- [F1]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.78 to 38.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F2]The option is fully vested and exercisable.
- [F3]The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Documents
Issuer
Adaptive Biotechnologies Corp
CIK 0001478320
Entity typeother
Related Parties
1- filerCIK 0001780656
Filing Metadata
- Form type
- 4
- Filed
- May 17, 8:00 PM ET
- Accepted
- May 18, 9:00 PM ET
- Size
- 13.0 KB